Who to call at Jasper Therapeutics, Inc., and when
Fundz watches for the moments Jasper Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Jasper Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Jasper Therapeutics, Inc., from your own LinkedIn network
Jasper Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.jaspertherapeutics.comAI Executive Summary
AI-powered analysis of 8-K filing content
Jasper Therapeutics' CFO Herb Cross resigned effective October 9, 2026, prompting the board to appoint interim replacements across financial and corporate governance roles. This leadership transition creates near-term uncertainty around financial oversight and strategic direction during a critical period for the biotech company.
Key Takeaways
Herb Cross resigned from CFO, Principal Financial Officer, Principal Accounting Officer, and Corporate Secretary roles due to other professional pursuits
Jeet Mahal (President and CEO) assumed interim Principal Financial Officer duties, creating dual responsibilities at the executive level
2 more takeaways
Filing Overview
What This Means
Jasper Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.